Shots:

• The P-III VISIBLE 2 study involves assessing of Entyvio (108 mg- SC) vs PBO SC as a maintenance therapy in 644 patients with moderately to severely active CD who achieved CR @6wks. following two doses of Entyvio (300 mg IV) at weeks 0 and 2
• The P-III VISIBLE 2 study resulted in meeting its 1EPs i.e- clinical remission @ 52wks. compared to PBO- no new safety signals were observed
• Entyvio is a gut-selective biologic act by inhibiting alpha4beta7 integrin binding to MAdCAM-1- approved as an IV formulation for UC & CD. Entyvio SC is under EMA & FDA’s review for ulcerative colitis

Click here to read full press release/ article

Ref: Takeda | Image:Takeda